1 Determination of vancomycin exposure target and individualized dosing

2 recommendations for ICU neonates: model informed precision dosing

Zhe Tang[1], Jing Guan[1], Jingjing Li[2], Yanxia Yu[2], Miao Qian[3], Jiang Cao[1], Weiwei Shuai[1],

Zheng Jiao[4,*]

[1]Department of Pharmacy, Women's Hospital of Nanjing Medical University, Nanjing

Maternity and Child Health Care Hospital, Nanjing, China

[2]Department of Pharmacy, Suzhou Municipal Hospital, Suzhou, China

[3]Department of Neonatology, Women's Hospital of Nanjing Medical University, Nanjing

Maternity and Child Health Care Hospital, Nanjing, China

[4]Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University,

Shanghai, China

Running Head: exposure target of vancomycin for neonates

*Correspondence author

Zheng Jiao, jiaozhen@online.sh.cn

ORCID: 0000-0001-7999-7162

Tel: 8621 2220 0000 ext 3021

Fax: 8621 2220 0000 ext 3021

Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University

241 Huai-hai West Road, 200030, Shanghai, China.

Abstract

Background: Few studies incorporating population pharmacokinetic/pharmacodynamic (Pop-PK/PD) modeling have been conducted to quantify the exposure target of vancomycin in neonates.

Objectives: (i) to derive vancomycin exposure target considering both vancomycin-induced acute kidney injury (AKI) and clinical efficacy in ICU neonates; (ii) to optimize dosing regimen of vancomycin in neonates based on PK/PD modeling and simulation.

Methods: This retrospective observational cohort study was registered at chictr.org.cn (ChiCTR1900027919). A Pop-PK model was developed to estimate individual PK parameters. Thresholds of vancomycin exposure in predicting AKI or efficacy were identified via classification and regression tree (CART) analysis. The association between exposure thresholds and clinical outcomes including AKI and efficacy was detected by logistic regression. Dosing recommendations were designed using Monte Carlo (MC) simulations based on the optimized exposure target.

Results: There were 182 neonates with 411 observations included in Pop-PK modeling. Covariate analysis showed that neonatal physiological maturation, renal function and conmitant use of vasoactive drugs (VAS) significantly affected vancomycin pharmacokinetics. AKI were screened for all patients. $AUC_{0-24} \geq 485$ mg·h/L was an independent risk factor for AKI when adjusting for co-administration of VAS. Clinical efficacy of vancomycin was analyzed in 42 patients with blood culture-proved staphylococcal sepsis. $AUC_{0-24}/MIC \geq 234$ was the only significant predictor for clinical

effectiveness. MC simulations indicated that regimens in Neonatal Formulary 7 and Red

Book (2018) were not suitable for all the neonates.

Conclusions: AUC_{0-24} of 240~480 assuming MIC=1 mg/L is a recommended exposure

target of vancomycin in neonates. The model informed dosing regimens are valuable in

clinical practice.

Key words: vancomycin, neonate, population pharmacokinetic modeling, acute kidney

injury, efficacy, AUC

Introduction

Neonates are predisposed to late-onset sepsis owing to their compromised immunity. *Staphylococcus aureus* and *other Staphylococcus spp.* are the predominant pathogenic bacteria. Vancomycin is the first-line choice against staphylococcal sepsis for ICU neonates[1].

Recent consensus guideline[2] supports a Bayesian-derived AUC/MIC of 400 to 600 (assuming MIC=1 mg/L) as the vancomycin exposure target for adults infected by MRSA. Bayesian-derived AUC monitoring is advocated while trough target-based dosing is not recommended given that an identical trough value can be derived from a wide range of daily AUC values[2, 3].

Several published reports in adults have examined vancomycin exposure-outcome relationship incorporating population pharmacokinetic/pharmacodynamic (Pop-PK/PD) modeling[4-9]. Comparatively, few exposure-outcome evaluations have been conducted in neonates[10]. Vancomycin is known as a potential nephrotoxin. However, its exposure threshold associated with vancomycin-induced acute kidney injury (AKI) has not been clearly defined in neonates[10]. The association between vancomycin exposure and clinical efficacy fails to be clarified in this population either[11]. Thus, there is a critical need for clinical studies in neonates that associate individual exposure with clinical outcomes incorporating AKI and efficacy.

This study aimed: (i) to derive vancomycin exposure target that balances both AKI and efficacy in ICU neonates, with a focus on AUC/MIC; (ii) to optimize neonatal dosing

recommendations of vancomycin by using Monte Carlo (MC) simulation according to the

exposure target obtained and the established Pop-PK model.

Patients and methods

Ethics

A retrospective observational cohort study was conducted and executed in accordance with

the recommendations of the Declaration of Helsinki (2000). The protocol was approved by

the Ethics Committee of Nanjing Maternity and Child Health Care Hospital. Identities of

patients were hidden during the study. Informed consent was approved unnecessary due to

retrospective nature of the study. This study was registered at chictr.org.cn

(ChiCTR1900027919).

Study population

The electronic medical records of patients who accepted vancomycin treatment in neonatal

ICU from 1st January 2016 to 31st December 2019 were reviewed to determine eligibility.

Patients with postmenstrual age (PMA)≤48 weeks when vancomycin initiated were

included. All individuals with normal renal function were treated by vancomycin for ≥3

days with at least one vancomycin serum concentration monitored. The exclusion criteria

included patients with incomplete data or vancomycin serum concentrations below the

limit of detection and patients with baseline serum creatinine (SCR) ≥81 μmol/L[12] prior to

vancomycin treatment.

Information of interest included: demographic information, dosing history, vancomycin

serum concentration, SCR, creatinine clearance (CLCR), co-medications, clinical

diagnosis, radiographic examinations, and microbiological culture. CLCR was calculated

by Schwartz equation[13] (Equation 1) as below:

$$\text{CLCR}\,[(\text{ml} \cdot \text{min}^{-1})/1.73\text{m}^2] = \frac{K \times HT(cm) \times 92.83}{SCR(\mu mol/L) + 10.79} \quad (1)$$

Where HT is body length of neonates, SCR is serum creatinine and K is a constant equal

to 0.33 (preterm neonates with PMA<37 weeks) or 0.45 (term neonates with PMA≥37

weeks).

According to the local protocol, neonates with suspected or confirmed sepsis received

empirical therapy with vancomycin in combination with meropenem based on presumptive

diagnosis. Once a diagnosis was established, anti-infectives were rationalized to cover the

causative pathogen.

Vancomycin (Vancocin, Lilly, S.A, Suzhou, China) was administered 10~15 mg/kg every

8 to 18 h with intermittent infusion lasting 60 min. Blood samples were collected 0.5 h

before vancomycin administration (trough) or 0.5 h after infusion completion (peak) prior

to the fourth or fifth dose. Target trough levels were 10 to 20 mg/L[14].

Bioanalytical method

Vancomycin concentrations were analyzed by fluorescence polarization immunoassay

with an ARCHITECT i2000SR (Abbott Laboratories, Chicago, IL, USA) within 24 h after

samples obtained. The limit of detection was 1 mg/L, and the calibration range was 3 to

100 mg/L. The intra-day and inter-day coefficients of variation (CV) were less than 20%.

SCR were analyzed through enzymatic method (Beckman Coulter AU5800, Beckman

Coulter Inc., Brea CA, USA) with linearity from 5 to 13275 μmol/L. The intra-day and

inter-day CVs were less than 5%.

Etiological examinations were provided by clinical laboratory of our hospital using VITEK

2 microbial identification system (bioMérieux, Lyon, France). The broth microdilution

(BMD) method was used to determine MICs. The interpretative reports were issued by

laboratory technicians according to CLSI criteria[15].

Pop-PK modeling

A Pop-PK model was developed to estimate PK parameters by nonlinear mixed effect

modeling software Monolix (version 2019R2, Lixoft, France) with Stochastic

Approximation Expectation Maximization (SAEM) algorithm.

One or two compartment model with first-order elimination was examined to fit the dataset.

Interindividual variabilities of PK parameters were estimated using an exponential model.

Residual unexplained variabilities were tested by an additive model, an exponential model,

or a combined additive and exponential model. Potential covariates were screened and

concomitant medication present in less than 20% population was not going to be tested.

Five models were employed to describe the impacts of size (weight) and maturation (age)

on clearance (CL) (Table S1)[16-18]. The model with lowest Akaike information criteria (AIC)

and Bayesian information criteria (BIC) as well as appropriate estimates of parameter was

employed for further analysis[19]. The selection of covariates was determined using a

forward inclusion and a backward elimination process. Nested covariate models were

statistically compared using a likelihood ratio test on differences in the objective function

value (OFV). A reduction in OFV of 3.84 (p<0.05) for forward inclusion and an increase

in OFV of 6.63 (p<0.01) for backward elimination were the criteria for retaining a covariate

in the model.

The final model was internally assessed by visual inspection of goodness-of-fit plots,

normalized prediction distribution error (NPDE), and bootstrap[19-21]. The data from the

previous study by Li et al.[22] was used to validate the final model externally. The mean

prediction error (MPE) and mean absolute prediction error (MAPE) (Table S2) were

applied to calculate bias and imprecision of model predictions[23].

Estimation of individual exposure variables

Individual exposure variables for initial 48 h of vancomycin therapy, including day 1 AUC

(AUC_{0-24}), day 2 AUC (AUC_{24-48}), and cumulative day 1 and 2 AUC (AUC_{0-48}), were

estimated by Simulx (version 2019R2, Lixoft, France). Although no data on which AUC

(i.e: initial AUC or AUC at steady state (AUC_{ss})) to use in determining vancomycin

exposure target, exposure of initial therapy may be more appropriate because potential

influence on vancomycin CL by worsening of infection could be avoided, and AUC in first

48 h is critical for ICU neonates and has been associated to clinical outcomes in adults[9, 24].

Determination of the exposure target

(i) AKI analysis. AKI were screened for all patients. AKI definition included an increase

of SCR by 26.5 μmol/L within 48 h, or a SCR rise to ≥1.5 times from the baseline within

7 days, or a urine volume <0.5 ml/(kg·h) for 6 hours[25].

(ii) Efficacy analysis. The clinical efficacy was analyzed for patients with blood culture-

proved staphylococcal sepsis. Exclusion criteria were: vancomycin treatment ≤5 days,

polymicrobial infection or concomitant use of an antibiotic sensitive to the identified

staphylococcus. Vancomycin treatment failure was defined as positive blood culture at ≥5

days after initiation of treatment, recurrence of bacteremia within 30 days, or 30-day

mortality[5, 7, 24].

Thresholds of vancomycin exposure in predicting AKI or efficacy were derived using

classification and regression tree (CART) analysis (R package rpart, version 4.1-15). The

predictive performance of thresholds, comprising the CART-derived and other priori

defined ones, were evaluated using receiver operating characteristic (ROC) curves, along

with predictive matrices including negative and positive predictive values (NPV and PPV,

respectively) (R package pROC, version 1.16.2)[9, 26].

Logistic regression analyses were performed to quantify the association between

vancomycin exposure and clinical outcomes. Other potential confounding variables with P

<0.20 in the univariate analysis were included in multivariate analyses using a stepwise

approach and retained in the model[27]. If mutiple variables were correlated, only one of

them was tested. P values of ≤0.05 were considered statistically significant.

According to analyses of AKI and efficacy, the optimized exposure target was set as the

basis for the following dosing regimen design.

Model informed dosing regimen

Dosing regimens were designed and compared with recommendations in Neonatal

Formulary 7[28] and Red Book (2018)[29]. Virtual patients with different physiological

characters were employed for MC simulations. Demographic information was

obtained from Fenton growth chart[30]. 1000 replicates of each scenario were simulated to

detect the most proper scheme (R package mlxR, version 2.0.2).

Results

Study population

183 One hundred and eighty-five neonates diagnosed as neonatal sepsis received intermittent

184 intravenous infusion of vancomycin in our institution from 1st January 2016 to 31st

185 December 2019. There were 182 patients eligible for this study with 286 trough and 125

186 peak concentrations (Table S3). Two patients with incomplete data and one patient of

187 hematological malignancy were excluded (Figure 1).

Pop-PK modeling

A Pop-PK model was developed to estimate individual parameters. One compartment

model with first-order elimination was sufficient to fit the data. Proportional model was

chosen to describe residual unexplained variabilities. The detailed modeling process was

summarized in Table S4.

Both Model II with PMA and Model III had relatively lower AIC and BIC. Model II with

PMA was selected because of its simplicity. SCR, CLCR, and co-administration of

vasoactive drugs (VAS) were recognized as significant covariates on CL. Since SCR and

CLCR were correlated and performed equally, SCR was retained due to better clinical

accessibility. A 14% decrease in CL was associated with co-administration of VAS.

Moreover, current weight (cWT) was incorporated to the volume of distribution (V) for

physiological plausibility. The results of final model were listed in Table 1.

The goodness-of-fit plot of the final model showed no obvious bias or trend (Figure 2).

Results of NPDE generally satisfied the hypothesis of normal distribution (Figure 3). The

bootstrap analysis (n=2000) showed the final model was precise since the median

parameter estimates were close to those of the final model (Table 1).

Twenty-eight patients from the previous study by Li et al.[22] were included for the external

evaluation. All the observations were troughs. The medians for cWT, PMA, and SCR were

1.66 kg (range, 0.80 to 2.52 kg), 33.22 weeks (range, 28.28 to 36.71 weeks), and 35.42

µmol/L (range, 14.17 to 51.71 µmol/L) respectively. No one was co-mediated with VAS.

The MPE and MAPE for the final model were 3.97% (standard deviation, 19.88%) and

13.01% (standard deviation, 15.36%) respectively.

Since the external evaluation showed no obvious bias, we combined all the data to re-

estimate the PK parameters. The estimates did not show an apparent difference (Table S5).

Determination of the exposure target

(i) AKI analysis. Seven AKI cases were identified in total. Five occurred in day 3 after

vancomycin initiated, and two in day 4. VAS, which were prescribed to 39 patients, was

the major potential nephrotoxin besides vancomycin. VAS referred to milrinone, dopamine,

epinephrine, and norepinephrine in our institution. Six in seven AKI cases were co-

administered VAS.

Once AKI occurred, vancomycin dosages were adjusted immediately. Except for two

deaths, renal function improved among the other five AKI patients within five days of

therapy.

Patients who experienced AKI had higher baseline SCR and lower CLCR. Although there

was no statistical difference in daily dose between patients with and without AKI, AKI

patients had significantly higher vancomycin exposure quantified by AUC_{0-24}, AUC_{24-48}

and AUC_{0-48} owing to their decreased vancomycin CL. (Table 2).

In ROC curve analysis, AUC_{0-24}, AUC_{24-48}, and AUC_{0-48} significantly predicted AKI with

good performance (Figure 4(a)). The CART-derived threshold of $AUC_{0-24} \geq 485$ mg·h/L

had the highest predictive value with an area under ROC curve (AUC_{ROC}) of 0.74 (CI: 0.54,

0.94) (Table S6). PPV, which represented true-positive predictions of patients who

experienced AKI, was positively correlated with vancomycin exposure. When $AUC_{0-24} \geq 485$ mg·h/L, PPV increased more rapidly indicating additional risk of incidence of AKI

(Table S6). Therefore, this threshold was included in further multivariate regression

analysis.

In univariate regression analysis, PNA, persistent pulmonary hypertension of newborn

(PPHN), and concomitant use of VAS or furosemide were identified as potential

confounding factors that influenced AKI besides AUC_{0-24} (Table S7). Vancomycin trough

was not included in multivariate analysis because it was strongly correlated with AUC_{0-24}

(Spearman coefficient = 0.75, P <0.01). SCR and CLCR were also excluded as they were

included in the diagnostic criteria for AKI. In multivariate regression analysis, AUC_{0-}

$_{24} \geq 485$ mg·h/L was independently associated with AKI while adjusting for concomitant

use of VAS (Table 3).

(ii) Efficacy analysis. Seventy-nine patients had positive blood cultures. Thirty-one with

blood culture-proved non-staphylococcal sepsis, 4 with polymicrobial infections, and 2

with co-administration of an antimicrobial that affected the identified staphylococcal

species were excluded. Forty-two patients with blood culture-proved staphylococcal sepsis

were eligible for efficacy analysis (Figure 1). Sixteen of them were infected by *S. aureus*,

while the others by *other Staphylococcus spp.*

Seven patients experienced treatment failures. Three died during vancomycin treatment.

Four had positive blood culture results at ≥ 5 days after initiation of vancomycin, and

linezolid was served as an alternative. No one experienced a recurrence of bacteremia.

Despite insignificant difference in daily dosage and MICs between patients with and

without effective treatment, vancomycin exposures were much lower among ineffective

patients quantified by AUC_{0-24}/MIC, AUC_{24-48}/MIC and AUC_{0-48}/MIC (Table 2).

ROC analyses showed that AUC_{0-24}/MIC, AUC_{24-48}/MIC and AUC_{0-48}/MIC performed

well in prediction of efficacy (Figure 4(b)). The threshold of $AUC_{0-24}/MIC \geq 234$ had the

highest predictive value with AUC_{ROC} of 0.86 (CI: 0.71, 1.00) (Table S8). NPV, which

referred to true-negative predictions of patients who experienced treatment failure, was

negatively correlated with vancomycin exposure. When $AUC_{0-24}/MIC \geq 234$, PPV

maintained low indicating decreased risk of treatment failure (Table S8). That is why this

threshold was included in further analysis.

bWT and cWT were identified as potential confounding factors that influence efficacy

besides AUC_{0-24}/MIC by univariate regression analysis (Table S7). These two variables

were apparently correlated. cWT was included in multivariate analyses since it better

reflected the actual physiological status during vancomycin treatment. In multivariate

regression analysis, AUC_{0-24}/MIC$\geq$234 was the only significant factor associated with

efficacy (Table 3).

According to analyses above, the exposure target for vancomycin in neonates was set as

AUC_{0-24} of 240 to 480 with MIC assumed to 1 mg/L.

Model informed dosing regimen

The dosage recommendations by the references[28, 29] and this study were displayed in Table

S9 and Table 4 respectively.

Generally, patients with concomitant use of VAS required a reduced daily dose. The dosing

interval of every 24 h was suitable for extremely preterm patients (PMA<28 weeks) with

a dose of 12.5~20 mg/kg. For preterm patients with a PMA between 28 and 36 weeks,

proper dosing intervals varied from 12 to 24 h. Term neonates (PMA$\geq$37 weeks) required

dosing intervals between 8 and 12 h. Dosing intervals $\leq$8 h was unnecessary.

Our results suggested that the daily dose for extremely-low-birth-weight (ELBW) neonates

(cWT<1 kg) was 12.5 to 20 mg/kg. However, Neonatal Formulary 7[28] recommended a

daily dose of 20 mg/kg for all ELBW neonates. The maximum daily dose recommended

by Red Book (2018)[29] for these patients was 30 mg/kg. Quite a few of ELBW neonates

were obviously overdosed in these references. Table 4 also showed that a daily dose of 20

to 45 mg/kg was required for normal-birth-weight (NBW) neonates with cWT>2.7 kg and

SCR≤60 μmol/L. While Red Book (2018)[29] claimed a daily dose of 30 mg/kg for patients

(GA>28 week) with normal renal function (SCR< 61.7 μmol/L). Apparently, this regimen

was unable to satisfy the treatment needs for all NBW neonates.

Discussion

This is the first study in neonates uniquely utilizing Pop-PK/PD modeling with Bayesian

estimation to evaluate vancomycin exposure associated with clinical outcomes including

AKI and efficacy. With Bayesian estimation, PK/PD variability for vancomycin exposure-

outcomes evaluations is plausible to be quantified. Bayesian estimation also allows for

more accurate and reliable quantification of exposure parameters (i.e: AUC) with sparse

data. Moreover, using Pop-PK based MC simulations, dosing recommendations for

neonates can be derived based on the optimized exposure target.

The exposure threshold for vancomycin-induced AKI in neonates has been clearly defined

in this study for the first time. The threshold for AKI, AUC_{0-24} of 480 mg·h/L, is relatively

lower than previous report in children. Le et al.[31] suggests that AUC_{ss} over 24 h in children

should be less than 800 mg·h/L to minimize AKI risk. The time to AKI in Le's study ranged

from 1 to 15 days[31]. The reported threshold based on AUC_{ss} is probably inapplicable in

clinical practice because AKI may occur prior to steady state. AUC after the occurrence of

AKI is an inappropriate predictor for AKI because high exposure is not the cause of AKI

but the consequence.

In this study, concomitant use of VAS is not only a significant covariate on vancomycin

CL, but also a confounding factor in predicting AKI. Six in seven patients who experienced

AKI were co-mediated with VAS. Given that VAS has been reported as an independent

risk factor for the development of AKI among ICU neonates[32], vancomycin-induced AKI

is probably not only associated vancomycin exposure alone[2, 8, 9, 33]. Multivariate regression

analyses show high vancomycin exposure ($AUC_{0-24} \geq 485$ mg·h/L) remains an independent

predictor of AKI after adjusting for concomitant use of VAS. Although our study cannot

explain whether the threshold for AKI will change as a result of concomitant VAS use,

there is a reason to believe high vancomycin exposure in addition to VAS application

contributes to incidence of AKI.

Another point worth mentioning is renal functions of all AKI patients recovered with the

development of vancomycin treatment except two deaths, although they were under a high

vancomycin exposure when AKI occurred. Dosing regimens were adjusted without delay

and no other adverse reactions (ADR) were observed during their hospital stay. These

findings agree with previous pediatric report[34]. It indicates that neonates may be relatively

tolerant to high vancomycin exposure and vancomycin-induced renal impairments are

possibly reversible. The ongoing monitoring of both vancomycin serum concentrations and

SCR needs to be emphasized in clinical practice.

The lower limit of our exposure target is far below the lower limit for adults in recent

consensus guideline (AUC/MIC of 240 vs. 400)[2]. Considering that AUC/MIC of ≥ 300 or

≥ 400 did not show improved clinical effectiveness in neonates with staphylococcal sepsis

in the previous report by Padari et al.[11], it indicates that a lower AUC/MIC is still possible

to be effective for neonates. In the absence of other efficacy data in neonates to clarify

AUC/MIC necessary for clinical effectiveness against staphylococcal sepsis, the threshold

for efficacy needs to be validated in the furture.

The relationship between vancomycin exposure and clinical efficacy failed to be

discovered in previous pediatric and neonatal studies[11, 35]. In contrast, we found AUC_{0-24}/MIC$\geq$234 was strongly correlated with efficacy. Possible reasons for this disparity may

be caused by several factors. Primarily, the previous study by Hahn et al.[35] focus on patients

with various sites of infection while all patients in our study have bloodstream infection.

Considering several breakpoints reported by studies on different infectious diseases in

adults[4-7], the threshold of vancomycin exposure may be infectious site-dependent.

Secondly, the whole population of the previous study by Padari et al.[11] had a relatively low

vancomycin exposure with only 12% of patients achieved AUC/MIC$\geq$400 compared to 26%

in our study. The correlation between efficacy and AUC/MIC may be unable to be detected

due to AUC/MIC values concentrated within a narrow range.

In contrast to regimen designed in this study, dose recommendations in current referential

books are unsuitable for all neonates. The scheme of Neonatal Formulary 7[28] is merely

PMA-based while the regimen of Red Book (2018)[29] is based on GA and SCR. According

to our Pop-PK model, renal function and concomitant use of VAS are significant covariates

on CL and must be considered in regimen design. Furthermore, regimens in both

references[28, 29] are overdosed to ELBW neonates and the regimen of Red Book (2018)[29] is

inadequate for NBW neonates with normal renal function.

There are several limitations to our study. Firstly, our data were derived from a

homogeneous neonatal population who had bloodstream infection and were administered

vancomycin with intermittent infusion. Therefore, the optimized exposure target should be

extrapolated to other populations who may have different infection sites with caution.

Secondly, given the low morbidity of vancomycin-induced AKI[36] and high effective rate

of staphylococcal sepsis in neonates[2, 37], it is important to recognize that the optimized

exposure target has limited ability to predict AKI or efficacy. This target can only serve as

a guide that balances AKI and efficacy[9]. Finally, the sample size of this study is relatively

small. Our findings need to be validated further in large multi-centered prospective studies.

In conclusion, the exposure target of AUC_{0-24} of 240 to 480 assuming MIC=1 mg/L should

be advocated to achieve clinical efficacy while minimizing ADR for vancomycin treatment

in neonates. The model informed dosing regimens are valuable in clinical practice for ICU

neonates with staphylococcal sepsis.

Acknowledgements

We thank Dr Xiaohui Chen and other pediatricians from neonatal ICU of Nanjing

Maternity and Child Health Care Hospital. We are also grateful to Dr Xiaojun Ji (Nanjing

Chia Tai Tianqing Pharmaceutical Co., Ltd., Nanjing, China) for his assistance with figure

preparation.

Funding

This project was supported by Hospital Pharmacy Foundation of Nanjing Pharmaceutical

Association (No. 2019YX004).

Transparency declarations

None to declare.

Author contributions

Z.T. and Z.J. planned and organized this study. J.C. and WW.S. were responsible for

bioanalytical analysis. M.Q. reviewed the eligibility of patients. JJ.L. and YX.Y. provided

the data set for external validation. J.G. performed data management. Z.T. conducted the

pharmacokinetic analysis/simulations and wrote the first versions of the manuscript,

reviewed by Z.J. All authors revised and accepted the final version.

Supplementary data

Tables S1 to S9 are available as Supplementary data at JAC Online.

References

1.   Jacqz-Aigrain E, Zhao W, Sharland M et al. Use of antibacterial agents in the

neonate: 50 years of experience with vancomycin administration. *Semin Fetal Neonatal*

Med 2013; **18**: 28-34.

2.   Rybak MJ, Le J, Lodise TP et al. Therapeutic monitoring of vancomycin for serious

methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and

review by the American Society of Health-System Pharmacists, the Infectious Diseases

Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious

Diseases Pharmacists. *Am J Health Syst Pharm* 2020.

3.   Patel N, Pai MP, Rodvold KA et al. Vancomycin: we can't get there from here. *Clin*

Infect Dis 2011; **52**: 969-74.

4.   Brown J, Brown K, Forrest A. Vancomycin AUC24/MIC ratio in patients with

complicated bacteremia and infective endocarditis due to methicillin-resistant

Staphylococcus aureus and its association with attributable mortality during hospitalization.

Antimicrobial agents and chemotherapy 2012; **56**: 634-8.

5.   Gawronski KM, Goff DA, Jack B et al. A Stewardship Program's Retrospective

Evaluation of Vancomycin AUC24/MIC and Time to Microbiological Clearance in

Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia and Osteomyelitis.

Clinical Therapeutics 2013; **35**: 772-9.

6.   Casapao AM, Lodise TP, Davis SL et al. Association between vancomycin day 1

exposure profile and outcomes among patients with methicillin-resistant Staphylococcus

aureus infective endocarditis. *Antimicrob Agents Chemother* 2015; **59**: 2978-85.

7.   Song KH, Kim HB, Kim HS et al. Impact of area under the concentration-time

curve to minimum inhibitory concentration ratio on vancomycin treatment outcomes in

methicillin-resistant Staphylococcus aureus bacteraemia. *International journal of*

antimicrobial agents 2015; **46**: 689-95.

8.   Chavada R, Ghosh N, Sandaradura I et al. Establishment of an AUC 0–24

Threshold for Nephrotoxicity Is a Step towards Individualized Vancomycin Dosing for

Methicillin-Resistant Staphylococcus aureus Bacteremia. *Antimicrob Agents Chemother*

2017; **61**: e02535-16.

9.   Zasowski EJ, Murray KP, Trinh TD et al. Identification of Vancomycin Exposure-

Toxicity Thresholds in Hospitalized Patients Receiving Intravenous Vancomycin.

Antimicrobial agents and chemotherapy 2018; **62**.

10.   Jacqz-Aigrain E, Leroux S, Zhao W et al. How to use vancomycin optimally in

neonates: remaining questions. *Expert Rev Clin Pharmacol* 2015; **8**: 635-48.

11.   Padari H, Oselin K, Tasa T et al. Coagulase negative staphylococcal sepsis in

neonates: do we need to adapt vancomycin dose or target? *BMC Pediatr* 2016; **16**: 206.

12.   Avner ED, Niaudet P, Emma F et al. Pediatric Nephrology. London, UK: Springer-

Verlag Berlin Heidelberg 2016; 615-6.

13.   Schwartz GJ, Brion LP, Spitzer A. The Use of Plasma Creatinine Concentration for

Estimating Glomerular Filtration Rate in Infants, Children, and Adolescents. *Pediatric*

Clinics of North America 1987; **34**: 571-90.

14.   Ye Z-K, Chen Y-L, Chen K et al. Therapeutic drug monitoring of vancomycin: a

guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological

Society. *Journal of Antimicrobial Chemotherapy* 2016; **71**: 3020-5.

15.   CLSI. Performance Standards for Antimicrobial Susceptibility Testing. *CLSI*

supplement M100. Pennsylvania, USA: Wayne, 2020; 58-9.

16.   Wang C, Peeters MY, Allegaert K et al. A bodyweight-dependent allometric

exponent for scaling clearance across the human life-span. *Pharm Res* 2012; **29**: 1570-81.

17.   Holford N, Heo YA, Anderson B. A pharmacokinetic standard for babies and adults.

J Pharm Sci 2013; **102**: 2941-52.

18.   Ding J, Wang Y, Lin W et al. A Population Pharmacokinetic Model of Valproic

Acid in Pediatric Patients with Epilepsy: A Non-Linear Pharmacokinetic Model Based on

Protein-Binding Saturation. *Clin Pharmacokinet* 2014; **54**: 305-17.

19.   Byon W, Smith MK, Chan P et al. Establishing Best Practices and Guidance in

Population Modeling: An Experience With an Internal Population Pharmacokinetic

Analysis Guidance. *CPT Pharmacometrics Syst Pharmacol* 2013; **2**: e51.

20.   Ette EI. Stability and performance of a population pharmacokinetic model. *J Clin*

Pharmacol 1997; **37**: 486-95.

21.   Comets E, Brendel K, Mentré F. Computing normalised prediction distribution

errors to evaluate nonlinear mixed-effect models: The npde add-on package for R. *Comput*

Methods Programs Biomed 2008; **90**: 154-66.

22.   Li JJ, Liu YX, Tang L et al. Population Pharmacokinetics of Vancomycin in

Chinese Neonates. *Chin Pharm J* 2017; **52**: 1434-41.

23.   van der Meer AF MM, Touw DJ, Proost JH, Neef C. Optimal Sampling Strategy

Development Methodology Using Maximum A Posteriori Bayesian Estimation. *Ther Drug*

Monit 2011; **33**: 133-46.

24.   Lodise TP, Drusano GL, Zasowski E et al. Vancomycin exposure in patients with

methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough?

Clinical infectious diseases : an official publication of the Infectious Diseases Society of

America 2014; **59**: 666-75.

25.   Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. *Nephron*

Clin Pract 2012; **120**: c179-84.

26.   Rhodes NJ, O'Donnell JN, Lizza BD et al. Tree-Based Models for Predicting

Mortality in Gram-Negative Bacteremia: Avoid Putting the CART before the Horse.

Antimicrobial agents and chemotherapy 2016; **60**: 838-44.

27.   Zhang Z. Model building strategy for logistic regression: purposeful selection. *Ann*

Transl Med 2016; **4**: 111.

28.   Ainsworth SB. Neonatal Formulary 7: Drug Use in Pregnancy and the First Year

of Life. UK: Wiley Blackwell. BMJ., 2014; 520.

29.   Pediatrics AAo. Red Book: Report of the Committee on Infectious Diseases. In:

Kimberlin DW BM, Jackson MA, Long SS, ed. USA: Itasca, IL: American Academy of

Pediatrics, 2018; 918.

30.   Fenton TR, Sauve RS. Using the LMS method to calculate z-scores for the Fenton

preterm infant growth chart. *Eur J Clin Nutr* 2007; **61**: 1380-5.

31.   Le J, Ny P, Capparelli E et al. Pharmacodynamic Characteristics of Nephrotoxicity

Associated With Vancomycin Use in Children. *J Pediatric Infect Dis Soc* 2015; **4**: e109-

e16.

32.   Stojanovic V, Barisic N, Milanovic B et al. Acute kidney injury in preterm infants

admitted to a neonatal intensive care unit. *Pediatr Nephrol* 2014; **29**: 2213-20.

33.   Sinclair EA, Yenokyan G, McMunn A et al. Factors associated with acute kidney

injury in children receiving vancomycin. *The Annals of pharmacotherapy* 2014; **48**: 1555-

62.

34.   Le J, Vaida F, Nguyen E et al. Population-Based Pharmacokinetic Modeling of

Vancomycin in Children with Renal Insufficiency. *J Pharmacol Clin Toxicol* 2014; **2**:

1017-26.

35.   Hahn A, Frenck RW, Allen-Staat M et al. Evaluation of Target Attainment of

Vancomycin Area Under the Curve in Children With Methicillin-Resistant Staphylococcus

Aureus Bacteremia. *Ther Drug Monit* 2015; **37**: 619-25.

36.   Lestner JM, Hill LF, Heath PT et al. Vancomycin toxicity in neonates: a review of

the evidence. *Curr Opin Infect Dis* 2016; **29**: 237-47.

37.   Wang J, Zhang H, Yan J et al. Literature review on the distribution characteristics

and antimicrobial resistance of bacterial pathogens in neonatal sepsis. *The journal of*

maternal-fetal & neonatal medicine : the official journal of the European Association of

Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the

International Society of Perinatal Obstetricians 2020: 1-10.

Figures

Figure 1 Study flow

Figure 2 Goodness-of-fit plot of the final established Pop-PK model.

(a) Population predictions vs. observations. (b) Individual predictions (IPRED) vs. observations. The black solid lines are the reference lines, and black dashed lines are the loess smooth lines.

Figure 3. Normalized prediction distribution error (NPDE) plots for the final model.

(a) Histogram of NPDE values; (b) NPDE vs. the probability density. Black dashed lines, theoretical distribution. Blue dashed line, empirical distribution. (c) Scatter plot of the time vs. NPDE; (d) Scatterplot of serum concentrations (Cc) vs. NPDE. Blue filled dots, observed data; Black dashed lines, theoretical mean; Blue solid lines, empirical percentiles of observations; Blue-shaded area, 95% CI for the 5th and 95th percentiles of the predicted values. Pink-shaded area, 95% CI for the 50th percentiles of the predicted values; Red-shaded area, outliers. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.

Figure 4. Receiver operating characteristic (ROC) curves.

(a) ROC curves of AUC_{0-24}, AUC_{24-48} and AUC_{0-48} for prediction of AKI. (b) ROC curves of AUC_{0-24}/MIC, AUC_{24-48}/MIC and AUC_{0-48}/MIC for prediction of efficacy. AUC_{ROC}, area under the ROC curve.

508 **Tables**

509 **Table 1**. The estimates of the final model and 2000 bootstrap results

Parameter[a]	Final model		Bootstrap		Bias (%)[c]
	Estimate	RSE (%)[b]	Median	2.5%~97.5%	
Structure model parameter					
V_{pop} (L)	0.86	3.02	0.87	0.80 ~ 0.93	0.82
CL_{pop} (L/h)	0.09	2.11	0.09	0.08 ~ 0.09	0.69
beta1	2.35	1.20	2.29	1.94 ~ 2.66	-2.77
beta2	0.18	3.41	0.18	0.09 ~ 0.28	4.55
F_{VAS}	0.86	0.34	0.85	0.77 ~ 0.94	-1.28
Inter-individual variabilty					
V (%CV)	11%	24.20	14%	0.09 ~ 0.20	24.11
CL (%CV)	24%	6.85	23%	0.20 ~ 0.26	-2.11
Residual variability					
Proportional (%CV)	0.21	4.82	0.21	0.18 ~ 0.24	-0.47

$V = V_{pop} \times \left(\frac{cWT}{1.5}\right)$

$CL = CL_{pop} \times \left(\frac{cWT}{1.5}\right)^{0.75} \times \left(\frac{PMA}{32}\right)^{beta1} \times \left(\frac{30}{SCR}\right)^{beta2} \times F_{VAS}$

V_{pop}, population mean estimate for volume of distribution in a subject with a body weight
of 1.5 kg; cWT, current body weight; CL_{pop}, population mean estimate for vancomycin
clearance in a subject with a body weight of 1.5 kg; PMA, postmenstrual age; SCR, serum
creatinine; F_{VAS}. scaling factor of concomitant use of vasoactive drugs.

[a]V (%CV), interindividual variability of volume of distribution; CL (%CV), interindividual
variability of vancomycin clearance.

[b]RSE, relative standard error.

[c]Bias%, relative bias of estimates by Monolix to the median estimates by 2000 bootstrap
procedures. The rate of bias in fixed effects less than 5% was thought acceptable. It was

$$Bias(\%) = \frac{Median_{bootstrap} - Median_{final}}{Median_{final}} \times 100\%$$

521 calculated by the formula .

Table 2. Comparisons of demographic and PK/PD characteristics between patients with and without AKI / patients with and without effective treatment.

	Non-AKI patients (N=175) median (range/proportion)	AKI patients (N=7) median (range/proportion)	P	Effective patients (N=35) median (range/proportion)	Ineffective patients (N=7) median (range/proportion)	P
Maturation						
Gender	98/77(male/female)	4/3(male/female)	1.00	18/17(male/female)	5/2(male/female)	0.43
Gestational age (weeks)	30.43(22.29~41.29)	33.86(24.71~40.00)	0.20	31.00(24.43~40.00)	29.71(26.29~33.29)	0.32
Postnatal age (weeks)	1.71(0.14~12.43)	0.29(0.43~1.71)	<0.01	2.14 (0.43~4.86)	2.29 (0.57~3.71)	1.00
Postmenstrual age (weeks)	33.00(22.29~44.43)	34.00(26.29~40.57)	0.66	33.14(26.00~40.71)	32.14(26.71~34.43)	0.41
Birth weight (kg)	1.35(0.55~4.40)	1.74(0.77~3.05)	0.43	1.37(0.70~3.03)	0.95(0.77~1.18)	< 0.01
Current weight (kg)	1.54(0.55~5.57)	1.77(0.90~3.02)	0.71	1.50(0.78~2.98)	1.18(0.74~1.45)	< 0.01
Renal Function						
Serum creatinine (μmol/L)	28.20(3.90~77.50)	45.70(32.80~75.80)	<0.01	24.30(9.60~55.21)	22.80(10.70~44.40)	0.84
Creatinine clearance [(mL/min)/1.73m^2]	33.53(9.69~142.18)	24.60(15.01~29.97)	<0.05	38.40(17.55~81.95)	36.71(22.37~51.40)	0.60
PK/PD Parameters						
Daily dose (mg/kg)	29.79(12.96~62.07)	28.80(11.41~46.69)	0.28	29.68(16.25~45.30)	29.55(18.92~45.52)	0.65
Clearance [L/(h·kg)]	0.07(0.02~0.16)	0.03(0.03~0.04)	<0.01	0.06(0.04 ~ 0.16)	0.06(0.05 ~ 0.13)	0.77
Vancomycin trough (mg/L)	10.67(3.11~33.01)	23.50(13.88~51.36)	<0.01	10.76(3.14~23.98)	9.72(6.42~12.76)	0.22
AUC$_{0-24}$ (mg·h/L)	360(191~617)	489(270~788)	0.08	366(212~597)	285(238~412)	< 0.05

AUC$_{24-48}$ (mg·h/L)	531(265~978)	623(389~1066)	0.12	565(309~978)	436(320~546)	< 0.05
AUC$_{0-48}$ (mg·h/L)	891(456~1575)	1112(659~1854)	0.11	928(520~1575)	721(557~899)	<0.05
AUC$_{0-24} \geq 485$(mg·h/L)	17 (9.71%)	4 (57.1%)	<0.01	/	/	/
AUC$_{24-48} \geq 622$(mg·h/L)	42 (24.0%)	4 (57.1%)	0.07	/	/	/
AUC$_{0-48} \geq 1077$(mg·h/L)	36 (20.6%)	4 (57.1%)	<0.05	/	/	/
MIC (mg/L)	/	/	/	2.0 (0.5~2.0)	2.0 (2.0~2.0)	0.12
AUC$_{0-24}$/MIC≥ 234	/	/	/	30 (85.7%)	1 (14.3%)	<0.01
AUC$_{24-48}$/MIC≥ 278	/	/	/	22 (62.9%)	0 (0.00%)	<0.01
AUC$_{0-48}$/MIC≥ 450	/	/	/	23 (65.7%)	0 (0.00%)	<0.01
Comorbidities						
Patent ductus arteriosus	76 (43.4%)	7 (100.0%)	<0.01	10 (28.6%)	3 (42.9%)	0.66
Pneumonia	74 (42.3%)	4 (57.1%)	0.46	8 (22.9%)	3 (42.9%)	0.35
Bronchopulmonary dysplasia	41 (23.4%)	2 (28.6%)	0.67	5 (14.3%)	2 (28.6%)	0.58
Meningitis	36 (20.6%)	1 (14.3%)	1.00	4 (11.4%)	0 (0.00%)	1.00
Neonatal necrotic enterocolitis	31 (17.7%)	2 (28.6%)	0.61	5 (14.3%)	0 (0.00%)	0.57
Persistent pulmonary hypertension of newborn	14 (8.00%)	2 (28.6%)	0.12	2 (5.71%)	0 (0.00%)	1.00
Co-medication						
Meropenem	82 (46.9%)	7 (100.0%)	<0.01	11 (31.4%)	2 (28.6%)	1.00
Vasoactive drugs[a]	33 (18.9%)	6 (85.7%)	<0.01	2 (5.71%)	1 (14.3%)	0.43
Furosemide	26 (14.9%)	4 (57.1%)	<0.05	1 (2.86%)	1 (14.3%)	0.31
Ibuprofen	8 (4.57%)	0 (0.00%)	1.00	1 (2.86%)	0 (0.00%)	1.00
Outcome						
Mortality	13 (7.43%)	2 (28.6%)	0.10	0 (0.00%)	3 (42.9%)	< 0.01

524 *Continuous variables were compared by Mann-Whitney U tests, and dichotomous variables by Fisher exact tests.

525 [a]Vasoactive drugs, which are referred to milrinone, dopamine, epinephrine, and norepinephrine in our institution.

526 [b]AKI, acute kidney injury.

527   **Table 3**. Results of multivariate regression analysis.

Variable	adjusted OR (95% CI)	P
AKI analysis		
$AUC_{0-24} \geqslant 485$ (mg·h/L)	11.31 (1.95,65.54)	<0.01
Concomitant use of VAS[a]	24.23 (2.65,221.76)	<0.01
Efficacy analysis		
$AUC_{0-24}/MIC \geqslant 234$	36 (3.54,365.98)	<0.01

528   [a]VAS, vasoactive drugs, which are referred to milrinone, dopamine, epinephrine, and
529   norepinephrine in our institution.

530 **Table 4**. Results of model informed dosing regimens.

cWT[a] (kg)	PMA[b] (weeks)	SCR[c] (μmol/L)	Patients without VAS[d] (mg/kg)	Patients with VAS (mg/kg)
0.7~0.99	25~27	10	17.5~20, q24h	15~17.5, q24h
		25	15~17.5, q24h	15~17.5, q24h
		45	15~17.5, q24h	12.5~15, q24h
		60	15~17.5, q24h	12.5~15, q24h
		90	12.5~15, q24h	12.5~15, q24h
1.0 ~ 1.69	28 ~ 31	10	15~17.5, q18h	17.5~20, q24h
		25	12.5~15, q18h	17.5~20, q24h
		45	12.5~15, q18h	15~17.5, q24h
		60	12.5~15, q18h	15~17.5, q24h
		90	10~12.5, q18h	15~17.5, q24h
1.7 ~ 2.69	32 ~ 36	10	15~17.5, q12h	12.5~15, q12h
		25	12.5~15, q12h	10~12.5, q12h
		45	10~12.5, q12h	10~12.5, q12h
		60	10~12.5 q12h	10~12.5, q12h
		90	10~12.5, q12h	10, q12h
2.7 ~ 3.69	37 ~ 41	10	17.5~20, q12h	15~17.5, q12h
		25	15~17.5, q12h	12.5~15, q12h
		45	12.5~15, q12h	12.5~15, q12h
		60	12.5~15, q12h	12.5~15, q12h
		90	12.5~15, q12h	10~12.5, q12h
3.7 ~ 4.6	42 ~ 46	10	12.5~15, q8h	17.5~20, q12h
		25	12.5~15, q8h	15~17.5, q12h
		45	10~12.5, q8h	15, q12h
		60	10~12.5, q8h	15, q12h
		90	10, q8h	12.5~15, q12h

531 [a]cWT, current body weight.

532 [b]PMA, postmenstrual age.

533 [c]SCR, serum creatinine.

534 [d]VAS, vasoactive drugs, which are referred to milrinone, dopamine, epinephrine, and
535 norepinephrine in our institution.